Traditional enzyme discovery approaches often fail to explore the vast diversity of natural sequence space, limiting innovation in biocatalysis. The MetXtra™ platform was developed to overcome these limitations by integrating multiple advanced technologies into a single discovery workflow.
Industrial biocatalysis offers highly efficient and selective solutions for chemical and pharmaceutical processes. However, one of the key challenges remains: identifying enzymes that perform reliably under real industrial conditions.
With the MetXtra™ technology platform, we address this challenge by integrating multiple advanced technologies into a single discovery workflow.
![]()
MetXtra gives our customers access to a comprehensive database of previously undiscovered enzymes. The cutting-edge bioinformatics methods allow us to quickly and precisely identify the appropriate enzyme for their specific applications, giving them a significant competitive advantage.
- VP, Head of Research and Development at BRAIN Biotech Zwingenberg
BRAIN Biotech offers customers access to the MetXtra™ technology platform if they want to establish and optimize biocatalytic processes, develop novel enzyme solutions and generate IP or FTO.
A key advantage of the MetXtra™ platform is its integration into a broader development pipeline. Beyond discovery, BRAIN Biotech supports:
This enables a seamless transition from discovery to production, allowing companies to implement new enzyme solutions more efficiently.
Whether you are exploring new biocatalytic pathways or optimizing existing processes, BRAIN Biotech supports you from enzyme discovery to industrial implementation.
